Metabolic Syndrome Ups Odds of ARDS, Death in COVID-19

MONDAY, January 3, 2022 (HealthDay News). In hospitalized patients with COVID-19, having metabolic syndrome is associated with an increased likelihood of acute respiratory distress syndrome (ARDS) and mortality. According to a study released online on December 22. at JAMA Network Open.

Joshua L. Denson, MD of Tulane University School of Medicine in New Orleans. Colleagues conducted a multicenter cohort study to investigate. Results compare between patients with COVID-19 with metabolic syndrome (three or more: obesity, prediabetes or diabetes, hypertension, dyslipidemia; 5069 adults) and controls without metabolic syndrome (23,971 adults). The metabolic syndrome has an increased risk of ARDS and death from COVID-19.

Invasive mechanical ventilation, ARDS, and mortality (adjusted odds ratios of 1.32, 1.45, 1.36, and 1.19, respectively). The researchers found metabolic syndrome with increased hospitalization risk of intensive care unit (ICU). The risk of ARDS increased additively with each additional metabolic syndrome criterion (one criterion: 10.4%, two bars: 15.3%, three criteria: 19.3%, four criteria: 24.3%). As well as with long-term hospitalization and length of stay in the intensive care unit (median 8.0 vs. 6.8 days and 7.0 vs. 6.4 days, respectively).

“Given the high rates of metabolic syndrome, obesity, and diabetes in the United States. One hypothesis for why the United States leads the world in cases and deaths from COVID-19 could be the high prevalence of metabolic syndrome in this population,” the authors write. Write down.

Several authors disclosed financial ties to the pharmaceutical industry.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *